ACIU Stock Analysis: Buy, Sell, or Hold?
ACIU - AC Immune SA
$2.74
-0.05 (-1.79%)
▼
5d:
-3.18%
30d:
-8.97%
90d:
-5.84%
HOLD
MODERATE Confidence
Analysis Updated: May 18, 2026 12:00 AM ET
Earnings: Apr 29, 2026
0d
Get Alerted When ACIU Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ACIU trades at premium valuation expecting 21.3% growth. Hold existing positions but don't chase. Wait for better entry.
📊 HOLD: ACIU trades at premium valuation expecting 21.3% growth. Hold existing positions but don't chase. Wait for better entry.
In-depth Analysis How we analyze
Valuation Analysis: ACIU is currently trading at $2.74, which is considered oversold relative to its 30-day fair value range of $2.82 to $3.15. From a valuation perspective, the stock is trading at a premium (Forward PE: 24.1) compared to its historical average (13.5). At these levels, the market is pricing in 21.3% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, ACIU is in a downtrend. The price is currently testing key support at $2.66. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ACIU has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $8.94 (+220.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ACIU is in a downtrend. The price is currently testing key support at $2.66. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ACIU has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $8.94 (+220.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.82 -
$3.15
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
56.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 220.3% below Wall St target ($8.94)
- NEUTRAL: Trading at premium valuation - market expects 21.3% growth which is achievable
Trading Range Analysis
30-Day Trading Range
$2.82 -
$3.15
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$2.66
Resistance Level
$3.16
Current Trend
Downtrend
Technical data as of
May 18, 2026
Fundamental Context
Forward P/E (Next Year Est.)
24.05
Wall Street Target
$8.94
(+220.3%)
Revenue Growth (YoY)
13.0%
Valuation Premium vs History
+21.3% premium
PE vs Historical
24.1 vs 13.5
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+21.3%
(market-implied from PE analysis)
1-Year Target
$3.38
(+21%)
2-Year Target
$4.11
(+47%)
3-Year Target
$4.98
(+79%)
3-Yr Target (if PE normalizes)
(PE: 24→14)
PE COMPRESSION
$2.79
(+0%)
Earnings growth offset by PE compression
Share & Embed Analysis
Last updated: May 18, 2026 3:21 PM ET
Data refreshes hourly during market hours. Next update: 4:21 PM
Data refreshes hourly during market hours. Next update: 4:21 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ACIU showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$549 | 63 BUY |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$55 | 57 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$79 | 56 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$875 | 45 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 50 HOLD |
